FAGR Fagron SA

Fagron publishes agenda for 2025 annual shareholders meeting

Fagron publishes agenda for 2025 annual shareholders meeting

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2025 – 8 AM CET

Fagron publishes agenda for 2025 annual shareholders meeting

The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders on Monday 12 May 2025.

Agenda

The agenda includes the discussion of the annual report, the approval of the annual financial statements and the dividend proposal of €0.35 for the financial year 2024, and the approval of the remuneration policy.

The full agenda and further details can be found in the meeting documents.

Meeting and meeting documents

Fagron’s annual general meeting of shareholders will be held at its statutory seat, Venecoweg 20A, 9810, Nazareth (Belgium) and by audio and video conference on Monday 12 May 2025 at 3PM CET.

The convocation, including the agenda, and other documents related to this general meeting of shareholders can be found on the .

Further information

Ignacio Artola

Global Investor Relations Leader

Tel.

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
11/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE

Disclosure of notification received from Alychlo

Disclosure of notification received from Alychlo Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET Disclosure of notification received from Alychlo Fagron received a notification based on the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Alychlo NV. Notification by Alychlo NV On 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the disposal of voting securities or voting rights on 25 July 2024....

 PRESS RELEASE

Openbaarmaking van kennisgeving ontvangen van Alychlo

Openbaarmaking van kennisgeving ontvangen van Alychlo Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 18 juli 2025 – 18 CET Openbaarmaking van kennisgeving ontvangen van Alychlo Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van Alychlo NV. Kennisgeving van Alychlo NV Op 14 juli 2025 ontving Fagron een melding dat het belang van Alychlo NV de meldingsdrempel van 3% had overschreden als gevolg van de verkoop van stemrechtverlenende effecten of s...

Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq

Fagron N.V. : A serial compounder in the pharma land, we raise our tar...

We’ve raised our medium term estimates for Fagron, expecting mid-term sales growth of 8.3% versus guidance (high single digit), likely topped by 2% via M&A and further supported by rising (AA-OB at 20.8% for 2027) margins (21% by 2027). At ~13.3x (AA-OB) 2026 P/E, Fagron is valued attractively, leading us to raise our target price to €27 per share.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch